Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that in the TASKi3 Phase 2b clinical trial in rheumatoid arthritis (RA) patients who had failed to respond to at least one biologic treatment, the group treated with R788 (fostamatinib disodium) did not report significantly higher ACR 20, ACR 50, ACR 70 and DAS28 response rates than the placebo group at three months, and therefore, the trial failed to meet its efficacy endpoints. The objective components (CRP and ESR)* of these ACR scores did show a statistically significant difference; however, the subjective reported response rate components did not as compared to placebo. Although the ACR scores for the R788 group were within the expected range in this patient population, the reported placebo response rates were considerably higher than seen in any other previous study of RA biologic failure patients and rose unaccountably between week 6 (at which point the reported response rates between R788 and placebo were significantly different) and month 3 (when such reported response rates were no longer significantly different).

TASKi3 was the first clinical trial evaluating R788 in which anatomical changes in the patients' wrist and hands were evaluated using Magnetic Resonance Imaging (MRI) and scored using the RAMRIS (Rheumatoid Arthritis Magnetic Resonance Imaging Scoring) system. Those results showed improvements in the treated group versus the placebo group in the Synovitis and Osteitis scores, while the Erosion scores, known to be the slowest to change, showed no significant effect at three months. The most frequent adverse events were as expected from the earlier TASKi trials and appear to be manageable.

Rigel will host a conference call today at 7PM EDT/ 4PM PDT
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Saint-Gobain has acquired ZenPure, ... filtration products, mainly for the life sciences sector. ... in a state-of-the-art plant in Hangzhou, China ... the globe and will bolster the range of fluid ... acquisition is fully in line with the Group,s strategy ...
(Date:5/6/2015)...  Membership in Medicare Supplement plans continued to ... Strategy report released by Mark Farrah Associates (MFA).  ... Med Supp plans, covered approximately 11.2 million seniors ... from 2013. Between 2013 and 2014, enrollment in ... Though UnitedHealth was the segment growth leader, many ...
(Date:5/6/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/7qn2gf/global_insulin ) ... Insulin Patch Market Opportunity Analysis" report to ... ultrasound and iontophoresis are being used for the ... type of technique, their prices may vary which ... In long-term, it would be considered as inexpensive ...
Breaking Medicine Technology:Saint-Gobain Acquires ZenPure, a Specialist in Filtration Products 2Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Global Insulin Patch Market Opportunity Analysis 2015 2
(Date:5/6/2015)... (PRWEB) May 07, 2015 Device Patent Law ... 2015 — 11:00 a.m. – 12:30 p.m. EDT, http://www.fdanews.com/DevicePatentLaw ... in expensive patent lawsuits and claims that waste their time. ... of these cases could be prevented if devicemakers better understand ... latest court rulings and revisions to patent laws from all ...
(Date:5/6/2015)... 2015 As the exclusive hospital of the ... the Pirate Ship at Raymond James Stadium for all the ... first to be drafted into the “Bucs Babies” program last ... spend time with children, particularly those born at the Florida ... be Buccaneers fans. I really enjoyed my time participating in ...
(Date:5/6/2015)... 06, 2015 On April 27, 2015, ... Plastic Surgery ,” compiled quotes about cosmetic surgery from ... pop singer Iggy Azalea, and Gwyneth Paltrow. For the ... having plastic surgery themselves; only a couple ... its expectations of youth and beauty. (see: goo.gl/wSomih) , ...
(Date:5/6/2015)... Chesapeake, Va. (PRWEB) May 06, 2015 ... hospital in the state of Virginia to acquire ... Vinci® surgical robot. The system upgrade includes enhanced ... many minimally invasive procedures across a wide spectrum ... surgical options, reduced pain and quicker recovery times. ...
(Date:5/6/2015)... King of Prussia, PA (PRWEB) May 06, 2015 ... Business Process Outsourcing solutions to the Medicare Advantage, Medicare ... three finalists in the Continuity and Resilience Team category ... by the Business Continuity Institute to recognize the outstanding ... or operating in the North America Region, including the ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 2Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 3Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 2Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 3Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... CHICAGO, Jan. 26 The YMCA of Metropolitan Chicago ... residents to lead healthier lifestyles.According to the U.S. Department ... report they are not physically active. Poor diet and ... are overweight or obese are at increased risk for ...
... warm up chilly Chicago bus riders by heating ten bus shelters in the downtown area. ... following locations:, , 16 South ... @ Lake , 300 North Michigan Avenue @ Wacker ... 757 North Michigan Avenue @ Chicago , ...
... glucose scored worse on cognition tests, study found , , MONDAY, ... diabetes, higher average blood glucose (sugar) levels may be linked ... Researchers found that patients with higher levels of hemoglobin A1C ... 3 months) had significantly worse results while doing cognitive tasks ...
... an uncommon, but possible, reaction, study finds, , , ... take medications for attention-deficit hyperactivity disorder (ADHD) may ... hallucinations. , U.S. government experts reviewed clinical ... the commonly prescribed ADHD stimulant medications, such as ...
... Ill., Jan. 26 /PRNewswire/ -- Alma ... and radiofrequency-based aesthetic devices, announced today the FDA ... The UniForm is the fifth module available ... UniForm has received FDA clearance for "the temporary ...
... Prevent serious injuries from ,extreme, winter sports by following ... For many thrill-seekers, extreme ("x-treme") sports can be a ... long winter months. Recently televised events such as the ... sports, including downhill ski racing and jumping, snowboarding, snowmobiling, ...
Cached Medicine News:Health News:YMCA and Dominick's Offer Health and Wellness Options 2Health News:It's Cold Outside! Warm Up in Select Downtown Chicago Heated Bus Shelters Courtesy of TYLENOL(r) Warming Liquids 2Health News:Higher Blood Sugar Could Impair Thinking 2Health News:Hallucinations Are Rare Side Effects of ADHD Medications 2Health News:'X-Tremely' Dangerous Sports 2Health News:'X-Tremely' Dangerous Sports 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: